Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 75

1.

The predicted impact and cost-effectiveness of systematic testing of people with incident colorectal cancer for Lynch syndrome.

Kang YJ, Killen J, Caruana M, Simms K, Taylor N, Frayling IM, Snowsill T, Huxley N, Coupe VM, Hughes S, Freeman V, Boussioutas A, Trainer AH, Ward RL, Mitchell G, Macrae FA, Canfell K.

Med J Aust. 2019 Oct 8. doi: 10.5694/mja2.50356. [Epub ahead of print]

PMID:
31595523
2.

Premalignant lesions and gastric cancer: Current understanding.

Koulis A, Buckle A, Boussioutas A.

World J Gastrointest Oncol. 2019 Sep 15;11(9):665-678. doi: 10.4251/wjgo.v11.i9.665. Review.

3.

Macrophage spatial heterogeneity in gastric cancer defined by multiplex immunohistochemistry.

Huang YK, Wang M, Sun Y, Di Costanzo N, Mitchell C, Achuthan A, Hamilton JA, Busuttil RA, Boussioutas A.

Nat Commun. 2019 Sep 2;10(1):3928. doi: 10.1038/s41467-019-11788-4.

4.

A systematic review of risk-reducing cancer surgery outcomes for hereditary cancer syndromes.

Peacock O, Waters PS, Otero de Pablos J, Boussioutas A, Skandarajah A, Simpson JA, Warrier SK, Heriot AG.

Eur J Surg Oncol. 2019 Dec;45(12):2241-2250. doi: 10.1016/j.ejso.2019.06.034. Epub 2019 Jun 25. Review.

PMID:
31262600
5.

IL-33-mediated mast cell activation promotes gastric cancer through macrophage mobilization.

Eissmann MF, Dijkstra C, Jarnicki A, Phesse T, Brunnberg J, Poh AR, Etemadi N, Tsantikos E, Thiem S, Huntington ND, Hibbs ML, Boussioutas A, Grimbaldeston MA, Buchert M, O'Donoghue RJJ, Masson F, Ernst M.

Nat Commun. 2019 Jun 21;10(1):2735. doi: 10.1038/s41467-019-10676-1.

6.

Dietary Intake of Nutrients Involved in One-Carbon Metabolism and Risk of Gastric Cancer: A Prospective Study.

Dugué PA, Bassett JK, Brinkman MT, Southey MC, Joo JE, Wong EM, Milne RL, English DR, Giles GG, Boussioutas A, Mitchell H, Hodge AM.

Nutr Cancer. 2019;71(4):605-614. doi: 10.1080/01635581.2019.1577982. Epub 2019 Mar 15.

PMID:
30873873
7.

Frizzled-7 Is Required for Wnt Signaling in Gastric Tumors with and Without Apc Mutations.

Flanagan DJ, Barker N, Costanzo NSD, Mason EA, Gurney A, Meniel VS, Koushyar S, Austin CR, Ernst M, Pearson HB, Boussioutas A, Clevers H, Phesse TJ, Vincan E.

Cancer Res. 2019 Mar 1;79(5):970-981. doi: 10.1158/0008-5472.CAN-18-2095. Epub 2019 Jan 8.

PMID:
30622113
8.

Revised Australian national guidelines for colorectal cancer screening: family history.

Jenkins MA, Ait Ouakrim D, Boussioutas A, Hopper JL, Ee HC, Emery JD, Macrae FA, Chetcuti A, Wuellner L, St John DJB.

Med J Aust. 2018 Nov 19;209(10):455-460. Epub 2018 Oct 29.

PMID:
30359558
9.

Current mismatch repair deficiency tumor testing practices and capabilities: A survey of Australian pathology providers.

Mascarenhas L, Shanley S, Mitchell G, Spurdle AB, Macrae F, Pachter N, Buchanan DD, Ward RL, Fox S, Duxbury E, Driessen R, Boussioutas A.

Asia Pac J Clin Oncol. 2018 Dec;14(6):417-425. doi: 10.1111/ajco.13076. Epub 2018 Oct 7.

PMID:
30294856
10.

Family history-based colorectal cancer screening in Australia: A modelling study of the costs, benefits, and harms of different participation scenarios.

Dillon M, Flander L, Buchanan DD, Macrae FA, Emery JD, Winship IM, Boussioutas A, Giles GG, Hopper JL, Jenkins MA, Ait Ouakrim D.

PLoS Med. 2018 Aug 16;15(8):e1002630. doi: 10.1371/journal.pmed.1002630. eCollection 2018 Aug.

11.

Safety and Acceptability of Esophageal Cytosponge Cell Collection Device in a Pooled Analysis of Data From Individual Patients.

Januszewicz W, Tan WK, Lehovsky K, Debiram-Beecham I, Nuckcheddy T, Moist S, Kadri S, di Pietro M, Boussioutas A, Shaheen NJ, Katzka DA, Dellon ES, Fitzgerald RC; BEST1 and BEST2 study investigators.

Clin Gastroenterol Hepatol. 2019 Mar;17(4):647-656.e1. doi: 10.1016/j.cgh.2018.07.043. Epub 2018 Aug 9.

12.

'Why don't I need a colonoscopy?' A novel approach to communicating risks and benefits of colorectal cancer screening.

Emery JD, Pirotta M, Macrae F, Walker JG, Qama A, Jenkins M, Boussioutas A.

Aust J Gen Pract. 2018 Jun;47(6):343-349. doi: 10.31128/AJGP-11-17-4386.

13.

Down-regulation of a pro-apoptotic pathway regulated by PCAF/ADA3 in early stage gastric cancer.

Brasacchio D, Busuttil RA, Noori T, Johnstone RW, Boussioutas A, Trapani JA.

Cell Death Dis. 2018 May 1;9(5):442. doi: 10.1038/s41419-018-0470-8.

14.

The conundrum of quality in colonoscopy.

Chittleborough TJ, Luck A, Boussioutas A, Warrier S, Heriot AG.

ANZ J Surg. 2018 Apr;88(4):263-264. doi: 10.1111/ans.14265. No abstract available.

PMID:
29611360
15.

An orthotopic mouse model of gastric cancer invasion and metastasis.

Busuttil RA, Liu DS, Di Costanzo N, Schröder J, Mitchell C, Boussioutas A.

Sci Rep. 2018 Jan 16;8(1):825. doi: 10.1038/s41598-017-19025-y.

16.

Early relapses after adjuvant chemotherapy suggests primary chemoresistance in diffuse gastric cancer.

Pattison S, Mitchell C, Lade S, Leong T, Busuttil RA, Boussioutas A.

PLoS One. 2017 Sep 18;12(9):e0183891. doi: 10.1371/journal.pone.0183891. eCollection 2017.

17.

TOPGEAR: A Randomized, Phase III Trial of Perioperative ECF Chemotherapy with or Without Preoperative Chemoradiation for Resectable Gastric Cancer: Interim Results from an International, Intergroup Trial of the AGITG, TROG, EORTC and CCTG.

Leong T, Smithers BM, Haustermans K, Michael M, Gebski V, Miller D, Zalcberg J, Boussioutas A, Findlay M, O'Connell RL, Verghis J, Willis D, Kron T, Crain M, Murray WK, Lordick F, Swallow C, Darling G, Simes J, Wong R.

Ann Surg Oncol. 2017 Aug;24(8):2252-2258. doi: 10.1245/s10434-017-5830-6. Epub 2017 Mar 23.

PMID:
28337660
18.

Immunological battlefield in gastric cancer and role of immunotherapies.

Wang M, Busuttil RA, Pattison S, Neeson PJ, Boussioutas A.

World J Gastroenterol. 2016 Jul 28;22(28):6373-84. doi: 10.3748/wjg.v22.i28.6373. Review.

19.

Cross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1,065 patients.

Szász AM, Lánczky A, Nagy Á, Förster S, Hark K, Green JE, Boussioutas A, Busuttil R, Szabó A, Győrffy B.

Oncotarget. 2016 Aug 2;7(31):49322-49333. doi: 10.18632/oncotarget.10337.

20.

Tumor testing to identify lynch syndrome in two Australian colorectal cancer cohorts.

Buchanan DD, Clendenning M, Rosty C, Eriksen SV, Walsh MD, Walters RJ, Thibodeau SN, Stewart J, Preston S, Win AK, Flander L, Ouakrim DA, Macrae FA, Boussioutas A, Winship IM, Giles GG, Hopper JL, Southey MC, English D, Jenkins MA.

J Gastroenterol Hepatol. 2017 Feb;32(2):427-438. doi: 10.1111/jgh.13468.

21.

Risk factors for metachronous colorectal cancer following a primary colorectal cancer: A prospective cohort study.

Jayasekara H, Reece JC, Buchanan DD, Rosty C, Dashti SG, Ait Ouakrim D, Winship IM, Macrae FA, Boussioutas A, Giles GG, Ahnen DJ, Lowery J, Casey G, Haile RW, Gallinger S, Le Marchand L, Newcomb PA, Lindor NM, Hopper JL, Parry S, Jenkins MA, Win AK.

Int J Cancer. 2016 Sep 1;139(5):1081-90. doi: 10.1002/ijc.30153. Epub 2016 May 9.

22.

Point Mutations in Exon 1B of APC Reveal Gastric Adenocarcinoma and Proximal Polyposis of the Stomach as a Familial Adenomatous Polyposis Variant.

Li J, Woods SL, Healey S, Beesley J, Chen X, Lee JS, Sivakumaran H, Wayte N, Nones K, Waterfall JJ, Pearson J, Patch AM, Senz J, Ferreira MA, Kaurah P, Mackenzie R, Heravi-Moussavi A, Hansford S, Lannagan TRM, Spurdle AB, Simpson PT, da Silva L, Lakhani SR, Clouston AD, Bettington M, Grimpen F, Busuttil RA, Di Costanzo N, Boussioutas A, Jeanjean M, Chong G, Fabre A, Olschwang S, Faulkner GJ, Bellos E, Coin L, Rioux K, Bathe OF, Wen X, Martin HC, Neklason DW, Davis SR, Walker RL, Calzone KA, Avital I, Heller T, Koh C, Pineda M, Rudloff U, Quezado M, Pichurin PN, Hulick PJ, Weissman SM, Newlin A, Rubinstein WS, Sampson JE, Hamman K, Goldgar D, Poplawski N, Phillips K, Schofield L, Armstrong J, Kiraly-Borri C, Suthers GK, Huntsman DG, Foulkes WD, Carneiro F, Lindor NM, Edwards SL, French JD, Waddell N, Meltzer PS, Worthley DL, Schrader KA, Chenevix-Trench G.

Am J Hum Genet. 2016 May 5;98(5):830-842. doi: 10.1016/j.ajhg.2016.03.001. Epub 2016 Apr 14.

23.

Multivitamin, calcium and folic acid supplements and the risk of colorectal cancer in Lynch syndrome.

Chau R, Dashti SG, Ait Ouakrim D, Buchanan DD, Clendenning M, Rosty C, Winship IM, Young JP, Giles GG, Macrae FA, Boussioutas A, Parry S, Figueiredo JC, Levine AJ, Ahnen DJ, Casey G, Haile RW, Gallinger S, Le Marchand L, Thibodeau SN, Lindor NM, Newcomb PA, Potter JD, Baron JA, Hopper JL, Jenkins MA, Win AK.

Int J Epidemiol. 2016 Jun;45(3):940-53. doi: 10.1093/ije/dyw036. Epub 2016 Apr 10.

24.

Germline mutations in PMS2 and MLH1 in individuals with solitary loss of PMS2 expression in colorectal carcinomas from the Colon Cancer Family Registry Cohort.

Rosty C, Clendenning M, Walsh MD, Eriksen SV, Southey MC, Winship IM, Macrae FA, Boussioutas A, Poplawski NK, Parry S, Arnold J, Young JP, Casey G, Haile RW, Gallinger S, Le Marchand L, Newcomb PA, Potter JD, DeRycke M, Lindor NM, Thibodeau SN, Baron JA, Win AK, Hopper JL, Jenkins MA, Buchanan DD; Colon Cancer Family Registry Cohort.

BMJ Open. 2016 Feb 19;6(2):e010293. doi: 10.1136/bmjopen-2015-010293.

25.

TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG).

Leong T, Smithers BM, Michael M, Gebski V, Boussioutas A, Miller D, Simes J, Zalcberg J, Haustermans K, Lordick F, Schuhmacher C, Swallow C, Darling G, Wong R.

BMC Cancer. 2015 Jul 21;15:532. doi: 10.1186/s12885-015-1529-x.

26.

Lamina propria macrophage phenotypes in relation to Escherichia coli in Crohn's disease.

Elliott TR, Rayment NB, Hudspith BN, Hands RE, Taylor K, Parkes GC, Prescott NJ, Petrovska L, Hermon-Taylor J, Brostoff J, Boussioutas A, Mathew CG, Bustin SA, Sanderson JD.

BMC Gastroenterol. 2015 Jul 3;15:75. doi: 10.1186/s12876-015-0305-3.

27.

Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers.

van der Post RS, Vogelaar IP, Carneiro F, Guilford P, Huntsman D, Hoogerbrugge N, Caldas C, Schreiber KE, Hardwick RH, Ausems MG, Bardram L, Benusiglio PR, Bisseling TM, Blair V, Bleiker E, Boussioutas A, Cats A, Coit D, DeGregorio L, Figueiredo J, Ford JM, Heijkoop E, Hermens R, Humar B, Kaurah P, Keller G, Lai J, Ligtenberg MJ, O'Donovan M, Oliveira C, Pinheiro H, Ragunath K, Rasenberg E, Richardson S, Roviello F, Schackert H, Seruca R, Taylor A, Ter Huurne A, Tischkowitz M, Joe ST, van Dijck B, van Grieken NC, van Hillegersberg R, van Sandick JW, Vehof R, van Krieken JH, Fitzgerald RC.

J Med Genet. 2015 Jun;52(6):361-74. doi: 10.1136/jmedgenet-2015-103094. Epub 2015 May 15. Review.

28.

Defective macrophage handling of Escherichia coli in Crohn's disease.

Elliott TR, Hudspith BN, Rayment NB, Prescott NJ, Petrovska L, Hermon-Taylor J, Brostoff J, Boussioutas A, Mathew CG, Sanderson JD.

J Gastroenterol Hepatol. 2015 Aug;30(8):1265-74. doi: 10.1111/jgh.12955.

PMID:
25809337
29.

Role of p53 in the progression of gastric cancer.

Busuttil RA, Zapparoli GV, Haupt S, Fennell C, Wong SQ, Pang JM, Takeno EA, Mitchell C, Di Costanzo N, Fox S, Haupt Y, Dobrovic A, Boussioutas A.

Oncotarget. 2014 Dec 15;5(23):12016-26.

30.

Predictors of outcome after surgery for gastric cancer in a Western cohort.

Pattison S, Mann GB, Crosthwaite G, Lade S, Mitchell C, Leong T, Busuttil RA, Boussioutas A.

ANZ J Surg. 2016 Jun;86(6):469-74. doi: 10.1111/ans.12915. Epub 2014 Nov 12.

PMID:
25388659
31.

Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas.

Lin SJ, Gagnon-Bartsch JA, Tan IB, Earle S, Ruff L, Pettinger K, Ylstra B, van Grieken N, Rha SY, Chung HC, Lee JS, Cheong JH, Noh SH, Aoyama T, Miyagi Y, Tsuburaya A, Yoshikawa T, Ajani JA, Boussioutas A, Yeoh KG, Yong WP, So J, Lee J, Kang WK, Kim S, Kameda Y, Arai T, Zur Hausen A, Speed TP, Grabsch HI, Tan P.

Gut. 2015 Nov;64(11):1721-31. doi: 10.1136/gutjnl-2014-308252. Epub 2014 Nov 10.

32.

Clinical problem-solving. Spot diagnosis.

Stark Z, Campbell LJ, Mitchell C, James PA, Heath JA, Boussioutas A, Lynch C, Trainer AH.

N Engl J Med. 2014 Jun 5;370(23):2229-36. doi: 10.1056/NEJMcps1302661. No abstract available.

PMID:
24897087
33.

Cost-effectiveness of family history-based colorectal cancer screening in Australia.

Ouakrim DA, Boussioutas A, Lockett T, Hopper JL, Jenkins MA.

BMC Cancer. 2014 Apr 16;14:261. doi: 10.1186/1471-2407-14-261.

34.

Processed pseudogenes acquired somatically during cancer development.

Cooke SL, Shlien A, Marshall J, Pipinikas CP, Martincorena I, Tubio JM, Li Y, Menzies A, Mudie L, Ramakrishna M, Yates L, Davies H, Bolli N, Bignell GR, Tarpey PS, Behjati S, Nik-Zainal S, Papaemmanuil E, Teixeira VH, Raine K, O'Meara S, Dodoran MS, Teague JW, Butler AP, Iacobuzio-Donahue C, Santarius T, Grundy RG, Malkin D, Greaves M, Munshi N, Flanagan AM, Bowtell D, Martin S, Larsimont D, Reis-Filho JS, Boussioutas A, Taylor JA, Hayes ND, Janes SM, Futreal PA, Stratton MR, McDermott U, Campbell PJ; ICGC Breast Cancer Group.

Nat Commun. 2014 Apr 9;5:3644. doi: 10.1038/ncomms4644.

35.

A signature predicting poor prognosis in gastric and ovarian cancer represents a coordinated macrophage and stromal response.

Busuttil RA, George J, Tothill RW, Ioculano K, Kowalczyk A, Mitchell C, Lade S, Tan P, Haviv I, Boussioutas A.

Clin Cancer Res. 2014 May 15;20(10):2761-72. doi: 10.1158/1078-0432.CCR-13-3049. Epub 2014 Mar 21.

36.

Role of tumour molecular and pathology features to estimate colorectal cancer risk for first-degree relatives.

Win AK, Buchanan DD, Rosty C, MacInnis RJ, Dowty JG, Dite GS, Giles GG, Southey MC, Young JP, Clendenning M, Walsh MD, Walters RJ, Boussioutas A, Smyrk TC, Thibodeau SN, Baron JA, Potter JD, Newcomb PA, Le Marchand L, Haile RW, Gallinger S, Lindor NM, Hopper JL, Ahnen DJ, Jenkins MA.

Gut. 2015 Jan;64(1):101-10. doi: 10.1136/gutjnl-2013-306567. Epub 2014 Mar 10.

37.

Identification and validation of novel candidate protein biomarkers for the detection of human gastric cancer.

Humphries JM, Penno MA, Weiland F, Klingler-Hoffmann M, Zuber A, Boussioutas A, Ernst M, Hoffmann P.

Biochim Biophys Acta. 2014 May;1844(5):1051-8. doi: 10.1016/j.bbapap.2014.01.018. Epub 2014 Feb 7.

PMID:
24512919
38.

Risk of colorectal cancer for carriers of mutations in MUTYH, with and without a family history of cancer.

Win AK, Dowty JG, Cleary SP, Kim H, Buchanan DD, Young JP, Clendenning M, Rosty C, MacInnis RJ, Giles GG, Boussioutas A, Macrae FA, Parry S, Goldblatt J, Baron JA, Burnett T, Le Marchand L, Newcomb PA, Haile RW, Hopper JL, Cotterchio M, Gallinger S, Lindor NM, Tucker KM, Winship IM, Jenkins MA.

Gastroenterology. 2014 May;146(5):1208-11.e1-5. doi: 10.1053/j.gastro.2014.01.022. Epub 2014 Jan 17.

39.

Quantification and characterization of mucosa-associated and intracellular Escherichia coli in inflammatory bowel disease.

Elliott TR, Hudspith BN, Wu G, Cooley M, Parkes G, Quiñones B, Randall L, Mandrell RE, Fagerquist CK, Brostoff J, Rayment NB, Boussioutas A, Petrovska L, Sanderson JD.

Inflamm Bowel Dis. 2013 Oct;19(11):2326-38. doi: 10.1097/MIB.0b013e3182a38a92.

PMID:
23989750
40.

Interleukin-11 is the dominant IL-6 family cytokine during gastrointestinal tumorigenesis and can be targeted therapeutically.

Putoczki TL, Thiem S, Loving A, Busuttil RA, Wilson NJ, Ziegler PK, Nguyen PM, Preaudet A, Farid R, Edwards KM, Boglev Y, Luwor RB, Jarnicki A, Horst D, Boussioutas A, Heath JK, Sieber OM, Pleines I, Kile BT, Nash A, Greten FR, McKenzie BS, Ernst M.

Cancer Cell. 2013 Aug 12;24(2):257-71. doi: 10.1016/j.ccr.2013.06.017.

41.

Screening participation for people at increased risk of colorectal cancer due to family history: a systematic review and meta-analysis.

Ait Ouakrim D, Lockett T, Boussioutas A, Hopper JL, Jenkins MA.

Fam Cancer. 2013 Sep;12(3):459-72. doi: 10.1007/s10689-013-9658-3. Review.

PMID:
23700069
42.

Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil.

Lei Z, Tan IB, Das K, Deng N, Zouridis H, Pattison S, Chua C, Feng Z, Guan YK, Ooi CH, Ivanova T, Zhang S, Lee M, Wu J, Ngo A, Manesh S, Tan E, Teh BT, So JB, Goh LK, Boussioutas A, Lim TK, Flotow H, Tan P, Rozen SG.

Gastroenterology. 2013 Sep;145(3):554-65. doi: 10.1053/j.gastro.2013.05.010. Epub 2013 May 14.

PMID:
23684942
43.

Screening participation predictors for people at familial risk of colorectal cancer: a systematic review.

Ait Ouakrim D, Lockett T, Boussioutas A, Keogh L, Flander LB, Hopper JL, Jenkins MA.

Am J Prev Med. 2013 May;44(5):496-506. doi: 10.1016/j.amepre.2013.01.022. Review.

PMID:
23597814
44.

Determining epithelial contribution to in vivo mesenchymal tumour expression signature using species-specific microarray profiling analysis of xenografts.

Purdom E, Restall C, Busuttil RA, Schluter H, Boussioutas A, Thompson EW, Anderson RL, Speed TP, Haviv I.

Genet Res (Camb). 2013 Feb;95(1):14-29. doi: 10.1017/S0016672313000013. Epub 2013 Mar 18.

PMID:
23497823
45.

Are the common genetic variants associated with colorectal cancer risk for DNA mismatch repair gene mutation carriers?

Win AK, Hopper JL, Buchanan DD, Young JP, Tenesa A, Dowty JG, Giles GG, Goldblatt J, Winship I, Boussioutas A, Young GP, Parry S, Baron JA, Duggan D, Gallinger S, Newcomb PA, Haile RW, Le Marchand L, Lindor NM, Jenkins MA.

Eur J Cancer. 2013 May;49(7):1578-87. doi: 10.1016/j.ejca.2013.01.029. Epub 2013 Feb 22.

46.

Risk of metachronous colon cancer following surgery for rectal cancer in mismatch repair gene mutation carriers.

Win AK, Parry S, Parry B, Kalady MF, Macrae FA, Ahnen DJ, Young GP, Lipton L, Winship I, Boussioutas A, Young JP, Buchanan DD, Arnold J, Le Marchand L, Newcomb PA, Haile RW, Lindor NM, Gallinger S, Hopper JL, Jenkins MA.

Ann Surg Oncol. 2013 Jun;20(6):1829-36. doi: 10.1245/s10434-012-2858-5. Epub 2013 Jan 29.

47.

mTORC1 inhibition restricts inflammation-associated gastrointestinal tumorigenesis in mice.

Thiem S, Pierce TP, Palmieri M, Putoczki TL, Buchert M, Preaudet A, Farid RO, Love C, Catimel B, Lei Z, Rozen S, Gopalakrishnan V, Schaper F, Hallek M, Boussioutas A, Tan P, Jarnicki A, Ernst M.

J Clin Invest. 2013 Feb;123(2):767-81. doi: 10.1172/JCI65086. Epub 2013 Jan 16.

48.

Cancer risks for MLH1 and MSH2 mutation carriers.

Dowty JG, Win AK, Buchanan DD, Lindor NM, Macrae FA, Clendenning M, Antill YC, Thibodeau SN, Casey G, Gallinger S, Marchand LL, Newcomb PA, Haile RW, Young GP, James PA, Giles GG, Gunawardena SR, Leggett BA, Gattas M, Boussioutas A, Ahnen DJ, Baron JA, Parry S, Goldblatt J, Young JP, Hopper JL, Jenkins MA.

Hum Mutat. 2013 Mar;34(3):490-7. doi: 10.1002/humu.22262.

49.

The unfolded protein response is activated in Helicobacter-induced gastric carcinogenesis in a non-cell autonomous manner.

Baird M, Woon Ang P, Clark I, Bishop D, Oshima M, Cook MC, Hemmings C, Takeishi S, Worthley D, Boussioutas A, Wang TC, Taupin D.

Lab Invest. 2013 Jan;93(1):112-22. doi: 10.1038/labinvest.2012.131. Epub 2012 Oct 29.

50.

Screening practices of Australian men and women categorized as "at or slightly above average risk" of colorectal cancer.

Ait Ouakrim D, Lockett T, Boussioutas A, Keogh L, Flander LB, Winship I, Giles GG, Hopper JL, Jenkins MA.

Cancer Causes Control. 2012 Nov;23(11):1853-64. doi: 10.1007/s10552-012-0067-y. Epub 2012 Sep 26.

Supplemental Content

Loading ...
Support Center